Uniwersytet Medyczny W Lodzi

The medical center is at the forefront of research in interstitial lung disease associated with systemic connective tissue diseases and hypersensitivity disease. The institution is dedicated to exploring innovative therapies that aim to improve patient outcomes in these complex conditions.

• Comparative efficacy of pirfenidone and nintedanib
• Standard therapy with mycophenolate mofetil

Through rigorous clinical trials, the center is advancing the understanding of therapeutic options, providing valuable insights into the management of these challenging diseases.

Specializing in systemic sclerosis with interstitial lung disease, the center is pioneering research into combination therapies that could redefine treatment protocols. The focus is on enhancing the efficacy and safety of current treatment regimens.

• Nintedanib and tocilizumab combination therapy
• Standard treatments including methotrexate and mycophenolate mofetil

By leveraging advanced imaging techniques like high-resolution computed tomography, the center is setting new standards in the assessment and management of lung involvement in systemic sclerosis.

The center is a leader in addressing anemia in patients with chronic kidney disease on dialysis. It is committed to evaluating novel therapeutic agents that aim to maintain optimal hemoglobin levels, thereby improving patient quality of life.

• Efepoetin alfa versus darbepoetin alfa
• Hemoglobin level control in hemodialysis patients

Through its research, the center is contributing to the development of more effective anemia management strategies, ensuring better health outcomes for patients undergoing dialysis.

Focusing on presymptomatic diabetes type 1, the center is exploring cutting-edge cell therapies that hold promise for altering the disease course in pediatric patients. This research is crucial for early intervention strategies.

• Cell therapy with CD4+CD25+CD127- regulatory lymphocytes
• Anti-CD20 antibody therapy

By investigating the safety and efficacy of these innovative treatments, the center is paving the way for new therapeutic approaches that could significantly impact the management of type 1 diabetes in its early stages.